Zhongguancun announced that some drugs belonging to Beijing Huasu, Shandong Huasu, and Duoduo Pharmaceutical, which are holding subsidiaries of Sihuan Pharmaceutical, a wholly-owned subsidiary of the company, were selected in the “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue”. A total of 34 products in production were selected, including newly produced and sold products such as protamine sulfate injection and compound pancreatic acid. Products that originally entered the “Medical Insurance Catalogue 2024”, such as bisoprolol fumarate tablets and benidipine hydrochloride tablets, continue to be selected. Beijing Huasu's “Compound Chloridine Hydrochloride Injection” was transferred to the “Medical Insurance Catalogue 2025”, and Duoduo Pharmaceutical's “Ambroxol Hydrochloride Injection” was newly selected. The future sales situation of selected products may be affected by multiple factors such as changes in the market environment, and will not have a significant impact on the company's current business performance.

Zhitongcaijing · 1d ago
Zhongguancun announced that some drugs belonging to Beijing Huasu, Shandong Huasu, and Duoduo Pharmaceutical, which are holding subsidiaries of Sihuan Pharmaceutical, a wholly-owned subsidiary of the company, were selected in the “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue”. A total of 34 products in production were selected, including newly produced and sold products such as protamine sulfate injection and compound pancreatic acid. Products that originally entered the “Medical Insurance Catalogue 2024”, such as bisoprolol fumarate tablets and benidipine hydrochloride tablets, continue to be selected. Beijing Huasu's “Compound Chloridine Hydrochloride Injection” was transferred to the “Medical Insurance Catalogue 2025”, and Duoduo Pharmaceutical's “Ambroxol Hydrochloride Injection” was newly selected. The future sales situation of selected products may be affected by multiple factors such as changes in the market environment, and will not have a significant impact on the company's current business performance.